Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
Abstract Background Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The ai...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12879-021-06270-w |
id |
doaj-b5f7569698a94b3b812d7c20c30b2462 |
---|---|
record_format |
Article |
spelling |
doaj-b5f7569698a94b3b812d7c20c30b24622021-06-20T11:07:57ZengBMCBMC Infectious Diseases1471-23342021-06-0121111710.1186/s12879-021-06270-wTherapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosisXiuting Hu0Wei Cheng1Shengxian Fan2Yuhua Huang3Xi Chen4Zhiwei Jiang5Jian Wang6State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityDepartment of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese MedicineDepartment of General Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing UniversityDepartment of General Surgery, Jinling Hospital, Medical School of Nanjing UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityDepartment of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese MedicineDepartment of General Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing UniversityAbstract Background Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBS rats. Methods 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. Results The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBS rats. The diversity of intestinal fungi was significantly increased in SBS rats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBS rats. Conclusion Our study confirms the bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis.https://doi.org/10.1186/s12879-021-06270-wIntestinal bacterial and fungalDysbiosisShort bowel syndromeIntestinotrophic hormoneGlucagon-like peptide 2 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiuting Hu Wei Cheng Shengxian Fan Yuhua Huang Xi Chen Zhiwei Jiang Jian Wang |
spellingShingle |
Xiuting Hu Wei Cheng Shengxian Fan Yuhua Huang Xi Chen Zhiwei Jiang Jian Wang Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis BMC Infectious Diseases Intestinal bacterial and fungal Dysbiosis Short bowel syndrome Intestinotrophic hormone Glucagon-like peptide 2 |
author_facet |
Xiuting Hu Wei Cheng Shengxian Fan Yuhua Huang Xi Chen Zhiwei Jiang Jian Wang |
author_sort |
Xiuting Hu |
title |
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis |
title_short |
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis |
title_full |
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis |
title_fullStr |
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis |
title_full_unstemmed |
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis |
title_sort |
therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis |
publisher |
BMC |
series |
BMC Infectious Diseases |
issn |
1471-2334 |
publishDate |
2021-06-01 |
description |
Abstract Background Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBS rats. Methods 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. Results The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBS rats. The diversity of intestinal fungi was significantly increased in SBS rats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBS rats. Conclusion Our study confirms the bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis. |
topic |
Intestinal bacterial and fungal Dysbiosis Short bowel syndrome Intestinotrophic hormone Glucagon-like peptide 2 |
url |
https://doi.org/10.1186/s12879-021-06270-w |
work_keys_str_mv |
AT xiutinghu therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis AT weicheng therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis AT shengxianfan therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis AT yuhuahuang therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis AT xichen therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis AT zhiweijiang therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis AT jianwang therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis |
_version_ |
1721370484230062080 |